- Home
- ZURA vs ESEA Comparison
ZURA vs ESEA Comparison
Compare ZURA & ESEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | ESEA |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | United States | Greece |
| Employees | 40 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 492.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | ZURA | ESEA |
|---|---|---|
| Price | $5.23 | $76.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $13.00 | ★ $62.00 |
| AVG Volume (30 Days) | ★ 1.5M | 38.7K |
| Earning Date | 05-14-2026 | 06-17-2026 |
| Dividend Yield | N/A | ★ 4.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $1.07 |
| P/E Ratio | ★ N/A | $3.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $48.89 |
| 52 Week High | $7.25 | $78.76 |
Technical Indicators
Market Signals| Indicator | ZURA | ESEA |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 70.71 |
| Support Level | $5.17 | $63.64 |
| Resistance Level | $5.88 | $78.76 |
| Average True Range (ATR) | 0.40 | 2.38 |
| MACD | -0.03 | 0.70 |
| Stochastic Oscillator | 40.12 | 80.22 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.